The Sense of Purpose

Our Story

At Mirava Bio, we are driven by a singular mission: to bridge the gap in access to life-changing therapies for rare disease patients across Europe, the Middle East, and Eurasia (EMEE). Combining expertise, innovation, and passion, we empower rare disease companies to bring their Advanced Therapy Medicinal Products (ATMPs) to underserved regions, making a profound impact on global health.


A Smarter Go-To-Market Approach: The Mirava Bio Model

We created Mirava Bio to redefine how biotechs expand into Europe, the Middle East, and Eurasia (EMEE): offering a seamless, de-risked, and capital-efficient alternative to traditional market entry models.   Unlike conventional options that require huge upfront investments, fragmented partnerships, or years of infrastructure setup, we provide a plug-and-play commercialization platform that enables companies to plan, prepare, and execute their market expansion up to 3-4 years before launch, ensuring a faster time to market, optimized costs, and maximized commercial success.

 

How We Do It Differently

  • Early Planning & Market Optimization (Phase 1/2 & Phase 3) – Strategic guidance on clinical trial site selection, regulatory pathways (ODD, PIP, MAA applicant and/or holder), early health economic modeling, and HTA engagement to lay the foundation for successful commercialization.
  • One Team, One Contract, All-in-One Execution – A fully integrated approach that aligns regulatory, market access, medical, and commercial functions from the start, ensuring efficiency, cost control, and smooth execution.
  •  Accelerated Time-to-Market & Revenue Generation – Unlocking revenue before full approval via Early Access Programs, Named Patient Sales, and payer pre-engagement strategies.
  • Full Market Expansion Without Heavy Investment – No need to set up affiliates, legal entities, or costly infrastructure – we offer you our infrastucture, provide the necessary licensing, commercial teams, and distribution networks.
  • Post-Pricing Agreement Commercialization – Driving market access negotiations, sales force deployment, patient identification strategies, and supply chain execution to ensure long-term commercial success.

 

By engaging early in the process, we help biotech companies reduce financial risk, optimize resources, and ensure a structured, accelerated path to market entry, delivering life-changing therapies to patients faster, and more efficiently.

 

Built by Experts, Driven by Passion

At Mirava Bio, we are more than a company - we are a team of experts, innovators, and passionate individuals committed to transforming the rare disease landscape.

 

Mayank Jain, co-founder, Chairman & CFO, has led the launch of groundbreaking therapies, including Zolgensma, built billion-dollar businesses, and shaped strategic growth in complex healthcare markets.


Vincent Lévêque is a senior biotech executive with over 2 decades of experience in rare diseases and gene therapy across Europe, the Middle East, and Eurasia. He has successfully launched landmark therapies like Soliris and Zolgensma and built high-performing commercial operations at Novartis, Alexion, and Kiniksa. Currently Co-founder and CEO of Mirava Bio, Vincent is passionate about expanding access to innovative treatments and mentoring future industry leaders.


Dr. Vincent Metzler brings over 25 years of experience in the pharmaceutical and biotech industry, with executive roles since 2016.
He previously served as CEO of Kither Biotech and held senior leadership positions at Atara Biotherapeutics, Wilson Therapeutics, Alexion, Roche, and Amgen. Vincent specializes in commercial strategy and launch execution for rare and ultra-rare disease therapies across the EMEA region.
Vincent holds a PhD in Molecular Biology and is fluent in English, French, and German.


But Mirava Bio is more than just its founders. Our dedicated internal team brings together deep industry knowledge, operational excellence, and an unwavering commitment to ensuring that innovative therapies reach the patients who need them most. We built Mirava Bio to provide a smarter, faster, and more effective way for biotechs to bring life-changing treatments to underserved markets, because every patient deserves access, no matter where they live.

 

Our Commitment

We partner with biotech innovators to:

  • Unlock access to EMEE markets using our expertise in regulatory pathways, market access, and commercialization.
  • Minimize financial risk with a flexible, end-to-end platform tailored to the unique needs of orphan drugs, gene therapies, and ATMPs.
  • Accelerate time-to-market, ensuring patients gain access to breakthrough therapies faster.

 

Why We Do It

Globally, 7,000+ rare diseases affect more than 350 million people, yet only 20% of rare disease treatments are available in Europe - with little to no data on access in the Middle East and Eurasia.

We believe no patient should be left behind due to geographical, financial, or logistical barriers. By focusing on underserved markets, Mirava Bio is changing the landscape of rare disease access,one therapy at a time.

 

Our Mission

To become the Commercial Bio partner for rare disease biotechs, enabling them to expand globally while retaining control, minimizing financial risk, and maximizing the value of their therapies.

 

Because every patient deserves access to life-saving treatments,no matter where they live.